Browse > Article
http://dx.doi.org/10.5483/BMBRep.2013.46.2.226

Somatic mutation patterns and compound response in cancers  

He, Ningning (Department of Biological Sciences, Sookmyung Women's University)
Kim, Nayoung (Department of Biological Sciences, Sookmyung Women's University)
Yoon, Sukjoon (Department of Biological Sciences, Sookmyung Women's University)
Publication Information
BMB Reports / v.46, no.2, 2013 , pp. 97-102 More about this Journal
Abstract
The use of various cancer cell lines can recapitulate known tumor-associated mutations and genetically define cancer subsets. This approach also enables comparative surveys of associations between cancer mutations and drug responses. Here, we analyzed the effects of ~40,000 compounds on cancer cell lines that showed diverse mutation-dependent sensitivity profiles. Over 1,000 compounds exhibited unique sensitivity on cell lines with specific mutational genotypes, and these compounds were clustered into six different classes of mutation-oriented sensitivity. The present analysis provides new insights into the relationship between somatic mutations and selectivity response of chemicals, and these results should have applications related to predicting and optimizing thera-peutic windows for anti-cancer agents.
Keywords
Cancer mutation; Cell line enrichment analysis; Compound response; $GI_{50}$; NCI60;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Blagosklonny, M. V. (2004) Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle 3, 1035-1042.
2 Kim, N., He, N., Kim, C., Zhang, F., Lu, Y., Yu, Q., Stemke-Hale, K., Greshock, J., Wooster, R., Yoon, S. and Mills, G. B. (2012) Systematic analysis of genotype-specific drug responses in cancer. Int. J. Cancer 131, 2456-2464.   DOI   ScienceOn
3 Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D. and Boyd, M. R. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48, 4827-4833.
4 Kwei, K. A., Baker, J. B. and Pelham, R. J. (2012) Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection. PLoS One 7, e46518.   DOI
5 Blower, P. E., Verducci, J. S., Lin, S., Zhou, J., Chung, J. H., Dai, Z., Liu, C. G., Reinhold, W., Lorenzi, P. L., Kaldjian, E. P., Croce, C. M., Weinstein, J. N. and Sadee, W. (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6, 1483-1491.   DOI   ScienceOn
6 Sausville, E. A. and Holbeck, S. L. (2004) Transcription profiling of gene expression in drug discovery and development: the NCI experience. Eur. J. Cancer 40, 2544-2549.   DOI   ScienceOn
7 Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., Lee, C., Wagner, S. N., Li, C., Golub, T. R., Rimm, D. L., Meyerson, M. L., Fisher, D. E. and Sellers, W. R. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.   DOI   ScienceOn
8 Blower, P. E., Verducci, J. S., Lin, S., Zhou, J., Chung, J. H., Dai, Z., Liu, C. G., Reinhold, W., Lorenzi, P. L., Kaldjian, E. P., Croce, C. M., Weinstein, J. N. and Sadee, W. (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6, 1483-1491.   DOI   ScienceOn
9 Ikediobi, O. N., Davies, H., Bignell, G., Edkins, S., Stevens, C., O'Meara, S., Santarius, T., Avis, T., Barthorpe, S., Brackenbury, L., Buck, G., Butler, A., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Hunter, C., Jenkinson, A., Jones, D., Kosmidou, V., Lugg, R., Menzies, A., Mironenko, T., Parker, A., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Smith, R., Solomon, H., Stephens, P., Teague, J., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Reinhold, W., Weinstein, J. N., Stratton, M. R., Futreal, P. A. and Wooster, R. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5, 2606-2612.   DOI   ScienceOn
10 Nishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W. C., Waltham, M., Kouros-Mehr, H., Bussey, K. J., Lee, J. K., Espina, V., Munson, P. J., Petricoin, E. 3rd, Liotta, L. A. and Weinstein, J. N. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. U.S.A. 100, 14229-14234.   DOI   ScienceOn
11 Ehrich, M., Turner, J., Gibbs, P., Lipton, L., Giovanneti, M., Cantor, C. and van den Boom, D. (2008) Cytosine methylation profiling of cancer cell lines. Proc. Natl. Acad. Sci. U.S.A. 105, 4844-4849.   DOI   ScienceOn
12 Clavel, J. (2007) Progress in the epidemiological understanding of gene-environment interactions in major diseases: cancer. C. R. Biol. 330, 306-317.   DOI   ScienceOn
13 Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T. and Bates, S. E. (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46, 627-638.
14 Shankavaram, U. T., Reinhold, W. C., Nishizuka, S., Major, S., Morita, D., Chary, K. K., Reimers, M. A., Scherf, U., Kahn, A., Dolginow, D., Cossman, J., Kaldjian, E. P., Scudiero, D. A., Petricoin, E., Liotta, L., Lee, J. K. and Weinstein, J. N. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol. Cancer Ther. 6, 820-832.   DOI   ScienceOn
15 Lee, A. C., Shedden, K., Rosania, G. R. and Crippen, G. M. (2008) Data mining the NCI60 to predict generalized cytotoxicity. J. Chem. Inf. Model. 48, 1379-1388.   DOI   ScienceOn
16 Malumbres, M. (2007) Cyclins and related kinases in cancer cells. J. BUON 12(Suppl 1), S45-52.
17 Crow, R. T., Rosenbaum, B., Smith, R. 3rd, Guo, Y., Ramos, K. S. and Sulikowski, G. A. (1999) Landomycin A inhibits DNA synthesis and G1/S cell cycle progression. Bioorg. Med. Chem. Lett. 9, 1663-1666.   DOI   ScienceOn
18 Ahn, Y. J., Kim, H., Lim, H., Lee, M., Kang, Y., Moon, S., Kim, H. S. and Kim, H. H. (2012) AMP-activated protein kinase: implications on ischemic diseases. BMB Rep. 45, 489-495.   과학기술학회마을   DOI   ScienceOn
19 Keshavarz, P., Inoue, H., Nakamura, N., Yoshikawa, T., Tanahashi, T. and Itakura, M. (2008) Single nucleotide polymorphisms in genes encoding LKB1 (STK11), TORC2 (CRTC2) and AMPK alpha2-subunit (PRKAA2) and risk of type 2 diabetes. Mol. Genet. Metab. 93, 200-209.   DOI   ScienceOn
20 Uslu, R. and Bonavida, B. (1996) Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum. Cancer 77, 725-732.   DOI
21 Zhang, Z., Zhao, M., Li, Q., Zhao, H., Wang, J. and Li, Y. (2009) Acetyl-l-carnitine inhibits TNF-alpha-induced insulin resistance via AMPK pathway in rat skeletal muscle cells. Febs. Lett. 583, 470-474.   DOI   ScienceOn
22 Bonadona, V., Bonaiti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., Guimbaud, R., Buecher, B., Bignon, Y. J., Caron, O., Colas, C., Nogues, C., Lejeune-Dumoulin, S., Olivier-Faivre, L., Polycarpe-Osaer, F., Nguyen, T. D., Desseigne, F., Saurin, J. C., Berthet, P., Leroux, D., Duffour, J., Manouvrier, S., Frebourg, T., Sobol, H., Lasset, C. and Bonaiti-Pellie, C. (2011) Cancer risks associated with germline mutations in MLH1, MSH2 and MSH6 genes in Lynch syndrome. JAMA 305, 2304-2310.   DOI   ScienceOn
23 Konstantinova, L. S., Bol'shakov, O. I., Obruchnikova, N. V., Laborie, H., Tanga, A., Sopena, V., Lanneluc, I., Picot, L., Sable, S., Thiery, V. and Rakitin, O. A. (2009) One-pot synthesis of 5-phenylimino, 5-thieno or 5-oxo-1,2,3-dithiazoles and evaluation of their antimicrobial and antitumor activity. Bioorg. Med. Chem. Lett. 19, 136-141.   DOI   ScienceOn
24 Lopez-Knowles, E., Zardawi, S. J., McNeil, C. M., Millar, E. K., Crea, P., Musgrove, E. A., Sutherland, R. L. and O'Toole, S. A. (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 19, 301-309.   DOI   ScienceOn
25 Evidente, A., Kireev, A. S., Jenkins, A. R., Romero, A. E., Steelant, W. F., Van Slambrouck, S. and Kornienko, A. (2009) Biological evaluation of structurally diverse amaryllidaceae alkaloids and their synthetic derivatives: discovery of novel leads for anticancer drug design. Planta Med. 75, 501-507.   DOI   ScienceOn
26 Ishihara, A., Yoshida, T., Tamaki, H. and Sakakura, T. (1995) Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin. Cancer Res. 1, 1035-1041.
27 Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix- Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R. and Futreal, P. A. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.   DOI   ScienceOn
28 Alonso, C. M., Such, E., Gomez-Segui, I., Cervera, J., Martinez-Cuadron, D., Luna, I., Ibanez, M., Lopez-Pavia, M., Vera, B., Navarro, I., Senent, L. and Sanz Alonso, M. A. (2012) BRAF V600E mutation in adult acute lymphoblastic leukemia. Leuk. Lymphoma [Epub ahead of print].
29 Ikediobi, O. N., Reimers, M., Durinck, S., Blower, P. E., Futreal, A. P., Stratton, M. R. and Weinstein, J. N. (2008) In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol. Cancer Ther. 7, 1337-1346.   DOI   ScienceOn
30 Scott, S. A., Dong, W. F., Ichinohasama, R., Hirsch, C., Sheridan, D., Sanche, S. E., Geyer, C. R. and Decoteau, J. F. (2006) 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leuk. Res. 30, 69-76.   DOI   ScienceOn
31 Amatori, S., Papalini, F., Lazzarini, R., Donati, B., Bagaloni, I., Rippo, M. R., Procopio, A., Pelicci, P. G., Catalano, A. and Fanelli, M. (2009) Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 66, 184-190.   DOI   ScienceOn
32 de Hoon, M. J., Imoto, S., Nolan, J. and Miyano, S. (2004) Open source clustering software. Bioinformatics 20, 1453-1454.   DOI   ScienceOn
33 Cheng, T., Wang, Y. and Bryant, S. H. (2010) Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules. Bioinformatics 26, 2881-2888.   DOI   ScienceOn
34 Kirchheiner, J., Fuhr, U. and Brockmoller, J. (2005) Pharmacogenetics- based therapeutic recommendations- ready for clinical practice? Nat. Rev. Drug Discov. 4, 639-647.   DOI   ScienceOn
35 Altmann, A., Daumer, M., Beerenwinkel, N., Peres, Y., Schulter, E., Buch, J., Rhee, S. Y., Sonnerborg, A., Fessel, W. J., Shafer, R. W., Zazzi, M., Kaiser, R. and Lengauer, T. (2009) Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. J. Infect. Dis. 199, 999-1006.   DOI   ScienceOn
36 Eisen, M. B., Spellman, P. T., Brown, P. O. and Botstein, D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95, 14863-14868.   DOI   ScienceOn